ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
ProMIS Neurosciences presented data at the 2026 Alzheimer’s Association International Conference showing dose-dependent reduction of amyloid-beta oligomers in cerebrospinal fluid of healthy volunteers after administration of its lead Alzheimer's drug candidate PMN310. This represents one of the first quantitative clinical evidences of target engage…